| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | CCNH; Cyclin-H; MO15-associated protein; p34; p37 |
| Entrez GeneID | 902 |
| WB Predicted band size | Calculated MW: 38 kDa; Observed MW: 38 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse |
| Immunogen | A synthetic peptide of human Cyclin H/p34 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是关于Cyclin H抗体的3篇参考文献示例(注：以下内容为模拟生成，实际文献需通过学术数据库检索确认)：
---
1. **文献名称**: "Purification and characterization of CAK, the CDK-activating kinase"
**作者**: Roy, R., Adamczewski, J.P., Seroz, T., et al.
**摘要**: 本研究通过免疫沉淀和亲和层析技术纯化了CDK7/Cyclin H复合物(CAK)，并利用特异性Cyclin H抗体验证其与CDK7的相互作用。研究揭示了CAK在CDK激活及RNA聚合酶II转录中的双重功能。
2. **文献名称**: "Cyclin H binding to CDK7 requires a structural interface critical for cell cycle progression"
**作者**: Lolli, G., Johnson, L.N.
**摘要**: 通过X射线晶体学解析CDK7/Cyclin H复合物结构，结合Cyclin H抗体的免疫印迹分析，阐明了二者结合的关键结构域。实验证明该界面突变会导致细胞周期G1/S期阻滞，提示其临床治疗潜力。
3. **文献名称**: "Dysregulation of Cyclin H in human cancers: A biomarker for tumor aggressiveness"
**作者**: Matsuoka, S., Edwards, M.C., Bai, C., et al.
**摘要**: 采用Cyclin H抗体对多种癌症组织进行免疫组化分析，发现Cyclin H在乳腺癌及肺癌中显著高表达，且与患者预后不良相关。研究提示Cyclin H可能作为癌症治疗的新靶点。
---
如需获取真实文献，建议通过PubMed或Google Scholar检索关键词“Cyclin H antibody”“CDK7/Cyclin H”等，并筛选涉及抗体实验(如Western blot、IP、IHC)的研究。
Cyclin H is a regulatory subunit of the cyclin-dependent kinase (CDK) family, primarily forming a complex with CDK7 to constitute the CDK-activating kinase (CAK). This complex plays a dual role in cell cycle regulation and transcriptional control. As part of the CAK, Cyclin H-CDK7 phosphorylates and activates CDKs (e.g., CDK1. CDK2. CDK4) involved in cell cycle progression, particularly at G1/S and G2/M checkpoints. Additionally, Cyclin H-CDK7 is a component of the general transcription factor TFIIH, facilitating RNA polymerase II-mediated transcription by phosphorylating its C-terminal domain. Dysregulation of Cyclin H expression or function has been linked to cancers, developmental disorders, and chemotherapy resistance.
Cyclin H antibodies are essential tools for studying its expression, localization, and interactions in cellular processes. They are widely used in techniques like Western blotting, immunohistochemistry, and co-immunoprecipitation to investigate Cyclin H's role in cell cycle control, transcriptional mechanisms, and disease pathogenesis. These antibodies also aid in exploring therapeutic targets, as CDK7 inhibitors (targeting the Cyclin H-CDK7 axis) are under investigation for cancer treatment. Validated Cyclin H antibodies help distinguish between active and inactive CAK complexes, providing insights into its regulatory mechanisms. Researchers rely on high-specificity antibodies to dissect Cyclin H's contribution to both proliferative and transcriptional programs in normal and pathological states.
×
